Last10K.com

Aclaris Therapeutics, Inc. (ACRS) SEC Filing 10-Q Quarterly report for the period ending Saturday, September 30, 2017

Aclaris Therapeutics, Inc.

CIK: 1557746 Ticker: ACRS

Exhibit 99.1

Aclaris Therapeutics Reports Third Quarter 2017 Financial Results

Management to Host Conference Call at 8:00 AM ET today

 

 

Malvern, PA – November 7, 2017 (GLOBE NEWSWIRE) –

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced financial results for the third quarter of 2017 and provided an update on its clinical development programs.   

“The third quarter of 2017 has been a productive one for Aclaris. In August, we closed the acquisition of Confluence Life Sciences, Inc. (“Confluence”), and we continue to prepare for our December 24th PDUFA date for A-101 40% Topical Solution for the treatment of seborrheic keratosis,” said Dr. Neal Walker, President and Chief Executive Officer of Aclaris.    

 

Clinical Pipeline Update

·

A-101 40% Topical Solution

o

In September, published results from a Phase 2 clinical trial evaluating two concentrations (40% and 32.5%) of its drug candidate A-101 for the treatment of facial seborrheic keratosis (SK) lesions in the journal Dermatologic Surgery. In the trial, A-101 achieved statistically significant improvement in clearing SK lesions on the face in a dose-related fashion. A-101 was well tolerated at both concentrations studied.

o

The FDA’s Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) is December 24, 2017. If approved, A-101 40% Topical Solution would be the first FDA-approved medication for SK.

 

·

A-101 45% Topical Solution

o

In June, initiated two Phase 2 clinical trials of A-101 45% Topical Solution (A-101 45%) for the treatment of common warts. The Phase 2 clinical trials are designed to evaluate the safety, tolerability and dose frequency of A-101 45% compared with placebo in adult and pediatric patients.  

 


The following information was filed by Aclaris Therapeutics, Inc. (ACRS) on Tuesday, November 7, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Aclaris Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aclaris Therapeutics, Inc..

Continue

Assess how Aclaris Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aclaris Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Consolidated Balance Sheets (parenthetical)
Consolidated Statement Of Stockholders' Equity
Consolidated Statement Of Stockholders' Equity (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Operations And Comprehensive Loss (parenthetical)
Consoliidated Balance Sheets
Accrued Expenses
Accrued Expenses (details)
Accrued Expenses (tables)
Acquisition Of Confluence
Acquisition Of Confluence (tables)
Acquisition Of Confluence - Fair Value Of Assets Acquired And Liabilities Assumed (details)
Acquisition Of Confluence - Summary Of Fair Valuel Consideration (details)
Acquisition Of Confluence - Supplemental Pro Forma Financial Information (details)
Agreements Related To Intellectual Property
Agreements Related To Intellectual Property (details)
Commitments And Contingencies
Commitments And Contingencies (details)
Commitments And Contingencies (tables)
Fair Value Of Financial Assets And Liabilities
Fair Value Of Financial Assets And Liabilities (detail)
Fair Value Of Financial Assets And Liabilities (tables)
Fair Value Of Financial Assets And Liabilities - By Type (details)
Income Taxes
Income Taxes (details)
Net Loss Per Share
Net Loss Per Share (details)
Net Loss Per Share (tables)
Net Loss Per Share - Anti-dilution (details)
Organization And Nature Of Business
Organization And Nature Of Business (details)
Organization And Nature Of Business - Ipo, Stock Split, Liquidity (details)
Property And Equipment, Net
Property And Equipment, Net (details)
Property And Equipment, Net (tables)
Related Party Transactions
Related Party Transactions (details)
Related Party Transactions (tables)
Stock-based Awards
Stock-based Awards (details)
Stock-based Awards (tables)
Stock-based Awards - Compensation (details)
Stock-based Awards - Option Activity (details)
Stock-based Awards - Rsus (details)
Stockholders' Equity
Stockholders' Equity (details)
Subsequent Events
Subsequent Events (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)
Ticker: ACRS
CIK: 1557746
Form Type: 10-Q Quarterly Report
Accession Number: 0001558370-17-008320
Submitted to the SEC: Tue Nov 07 2017 8:01:18 AM EST
Accepted by the SEC: Tue Nov 07 2017
Period: Saturday, September 30, 2017
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/acrs/0001558370-17-008320.htm